ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Pharmacy PHA

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. S.1954: Biosimilar Red Tape Elimination Act. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062 - RAPID Reserve Act. H.R.6992/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025.

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 2062 (119th), H.R. 1396 (119th), H.R. 1051 (119th), S. 1302 (119th), H.R. 3955 (119th), S. 1891 (119th), H.R. 6992 (119th), S. 1954 (119th), H.R. 4132 (119th), S. 1784 (119th), S. 2027 (119th), H.R. 1843 (119th)

Medicare/Medicaid MMM

Medicare Part D Reform. S.1414: Expedited Access to Biosimilars Act. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. H.R.1: One Big Beautiful Bill Act as it relates to Delinking in Medicare Part D, Medicaid Spread Pricing, PBM transparency, and NADAC Reporting.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC)

Bills named: S. 1414 (119th), H.R. 1 (119th)

Copyright/Patent/Trademark CPT

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269: Eliminating Thickets to Increase Competition (ETHIC) Act. S.1041: Affordable Prescriptions for Patients Act. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act. S.1097: Interagency Patent Coordination and Improvement Act of 2025.

Contacted: Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); White House Office; SENATE; Federal Trade Commission (FTC)

Bills named: S. 1095 (119th), H.R. 3152 (119th), S. 1096 (119th), S. 1097 (119th), S. 43 (119th), S. 1546 (119th), H.R. 3269 (119th), S. 1040 (119th), H.R. 3160 (119th), S. 1041 (119th), S. 1553 (119th)

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. H.R.2213/S.998: Medical Supply Chain Resiliency Act. H.R.1980: State Strategic Stockpile Act of 2025.

Contacted: Health & Human Services, Dept of (HHS); SENATE; Office of Management & Budget (OMB); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Natl Economic Council (NEC); Office of the Vice President of the United States; U.S. Customs & Border Protection; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); State, Dept of (DOS)

Bills named: H.R. 2213 (119th), H.R. 1980 (119th), S. 998 (119th)